|

            

            


Common
Types of
Fraud:



|
Fast
Facts
about
the
FCA
|
|
The Government Counts on Whistleblowers:
More than
80 percent of the False Claims Act cases that are now
pursued by the U.S. Department of Justice are initiated by
whistleblowers.
|
|
Cheaters Pay Whistleblower Awards:
Companies cheating the U.S. Government pay whistleblower
rewards – not one dime comes from U.S. taxpayers.
The reason for this is that the False Claims Act calls for
triple damages so that the Government can be made whole, not only
by recouping the cost of whistleblower awards, but also by
recovering the cost of investigations, prosecutions, and
lost interest.
|
|
Big
Cases Require Big Investments:
Big fraud cases prosecuted under the False Claims Act
often require many years of litigation and investigation.
For example, the whistleblower in the first Columbia-HCA
fraud case spent 13 years pursuing his False Claims Act
lawsuit. The law firm that spearheaded this case invested
more than 85,000 hours in
the case. In the end, the various frauds perpetrated by
Columbia-HCA returned over $1.5 billion to the U.S.
Treasury.
|
|
Frivolous Lawsuits are Discouraged:
Because most False Claims Act lawyers work on a contingency
basis, they only get paid if they win. This means that they
are unlikely to invest time, money and energy building a
case that they themselves do not feel will be productive.
In addition, under the False Claims Act, a complainant can
be required to pay the defendants attorney’s fees if the
court finds that the claim was frivolous or brought
primarily for purposes of harassment.
|
|
The
False Claims Act Provides Some Employment Protections:
If an employee is fired, demoted, harassed, or otherwise
discriminated against for filing a False Claims Act suit,
the law provides for reinstatement, double back pay, and
compensation for special damages, including litigation costs
and reasonable attorneys’ fees.
|
|
Drug Company Frauds are Pervasive and Large:
Over 180 pharmaceutical fraud cases, covering more than
500 drugs, are now under
investigation by the U.S. Department of Justice under the
False Claims Act.
Settlement of just 16 drug
manufacturing cases
(all those resolved to date) has returned over $4 billion
to the U.S. Government and the 50 states.
|
|
Routine Mistakes and Errors
are Not Prosecuted Under the False Claims Act:
The False Claims Act is not used to correct minor billing
mistakes or errors, as these frauds are not systematic and
rarely amount to truly large sums of money.
|
|
Major
Cases Under Watch:
|
|
Nominal Pricing Fraud:
FCA cases involving
violations of the nominal pricing exception have been
filed. Possible cases involve
statins, proton pump
inhibitors, non-steroidal anti-inflammatory drugs, and
others.
Iraq War Fraud:
Numerous large cases
dealing with contractor fraud in Iraq are reported to be
under investigation, but remain under seal.
Katrina Flood Insurance Fraud:
A large case
alleging fraud against the federal Flood Insurance Program
by
Nationwide,
Allstate and USAA insurance companies, as well as engineering firms that
examined property damage after Hurricane Katrina,
has come out from under seal and is being investigated by
the U.S. Government.
Anti-Psychotic Drugs:
Investigations
about the off-label marketing of Zyprexa, Risperdal and
Seroquel are under way. These three drugs
represented combined sales of $12 billion in
2006.
Average Wholesale Price Fraud:
The U.S. Government
has joined three cases likely to go to trial this summer:
Abbott, Dey and Roxane Pharmaceuticals. More than 50
other companies face similar charges in Boston.
University
of Phoenix:
The Supreme Court has denied cert., and the defendants
concede they face a billion dollars in liability. Trial
starts this summer.
Outlier
Fraud:
Several large outlier fraud investigations against hospitals
are under investigation.
|
|
Newsletters |
|
May 11,
2008
n
McKesson to Pay $13.25 Million
n
CoxHealth Floats a Number
n
Magical Millions
n
Wackenhut Under the Glass
May
2, 2008M
n
UMDNJ
Docs Sued for Kickbacks
n
GSA's Lurita Doan Loses Job
n
Are Fraud Files a Trade Secret?
n
Savannah Hospital Pays $5 Million
n
Cancer Doc Imports for Resale
n
"Undercover"
by John Schilling
n
New
York's Medicaid Work Plan
April
22, 2008
n
HHS
Say "Tell Us More"
n
It
Takes a Village to Detect Fraud
n
Positively Not Overnight
n
Fraud
Loophole Eliminated
April
15, 2007
n
Radiologist to Pay $7 Million
n
NC
Dental Chain Pays $10 Million
n
Heartland Dental Pays $3 Million
n
OMB has Some Explaining to Do
n
Entrepreneur of the Year?
n
Ista Off-Label Investigation
n
Fast
Fact: Inflation-adjusing FCA Penalties
April 3,
2008
False Claims Act Amendments
Voted Out Senate Judiciary Committee
March
31, 2008
n
Abilify Maker to Pay $4 Million
n
HealthEssentials Not Likely to Pay
Back Stolen Millions
n
AWP Class Action Certified
n
Derived Off-label Liability?
n
Psychiatrist to Pay $1.1 Million
March 19, 2008
n
CVS Pays $37 Million For Drug Switching
n
InterMune CEO Charged
n
Pfizer Sales Manager Indicted
n
Mounting Zyprexa Liability
n
Michigan Money on the Table
March
13, 2008
n
Former Pfizer Manager Indicted for
Obstruction
n
Yale-New Haven Hospital Settles
n
WellCare Hires a Fixer
n
Precursor to an AWP Settlement?
n
Besler to Pay $2.8 Million
March 6,
2008
n
Allison Engine at Supreme Court
n
Senate Judiciary Hearing on FCA
n
Cathedral to Pay $5.3 Million
February
25, 2008
n
Allison Engine to Supreme Court
n
$215 Million Alabama Jury Award
(non-FCA)
n
Quest Reserves $241 Million
n
Betting the House
n
Wisconsin Passes State FCA
February
15, 2008
n
Alabama
Takes on Pharma Fraud
n
Amgen Subpoenaed for
Enbrel
n
A
Free-Fraud Zone?
n
Counting False Claims Act Cases
n
Fight
Fraud: Remove The Cap
February
8, 2008
n
Merck
Settles for $650 Million
n
Alabama AWP Trial to Start
n
"Undercover" by John Schilling
n
Finally
A
Treatment
n
Lilly Sued Over Zyprexa as
Settlement Rumors Swirl
January
30, 2008
n
Big Dig False Claims Act
Case
n
Rhode Island False
Claims Act Signed Into Law
n
Feds Join NJ Outlier
Cases
n
Passion for Payola is
Called . . .
n
Washington Defines
Success
January 23, 2008
n
Supreme Court Gets Briefs in
Allison Engine Case
n
New Jersey False Claims
Act Signed Into Law
n
Louisiana Hospital to
Pay $1.9 Million for Heart Fraud
n
Apollo to Pay $282
Million
n
Illinois Expands Its FCA
n
Pharma Trinkets to
Cameroon
January
10, 2008
n
Washington D.C. To
Require Pharma Rep Sales Licenses
n
Fraud-fighting Without
Teeth
n
Orthofix in the
Crosshairs
n
Dey and Takeda Pay $6.75
Million
December
27, 2007
n
Fraud Costs Us More Than
an Arm and a Leg
n
SBA
Fraud Unprosecuted
n
$26 Million Hospital
Settlement
n
CMHS to Pay $1.5 Million
n
Orange County to Pay $7
Million
n
Illinois
Attorney
General Refiles on MRI Operators
n
Sioux Kevlar Case
December 18, 2007
n
Relator Wins Over DoJ
Protest
n
HealthSouth Pays
$14.9 Million
n
Law and Odor at Wellcare
n
Blue Cross and Blue
Shield
Does Payola Politics in RI
n
More Tricky Knee
Subpoenas
December 10, 2007
n
$42 Million Sand Theft
n
Ambulance
Co. to Pay $6 Million
n
Iraq: Money Without
Meter
n
Asphalt Co. Settles FCA
Case for $8.2 Million
n
NJ Hospital to Pay $7.5
Million
n
Cigarette Importation
FCA
n
Harris Hosp. Pays $1.9 Million
December 5, 2007
n
Merck Settlement Expected to Top $670
Million
n
$25 Million TVA Coal
Settlement
n
$25 Million Wheelchair
Fraud
OK Doctors to Pay
n
$1.5 Million
November
28, 2007
n
Sleep Center
Billing Fraud
n
Cheating Death and
Medicare
n
DoJ's Monitoring Contracts
n
The High Price of
Whistleblowing
n
Federal
Whistleblower Odds
November
20, 2007
n
DoJ Joins Suit
Against Lockheed
n
The Biggest FCA Case
Ever?
n
Peter Rost Gets a Second Chance
n
Second Stryker
Settlement: $16.5 Million
November 14, 2007
n
Off-Label Narcotic Lollipops
n
$28 Million Air Cargo Fraud
n
DaVita Investigation in Nevada
n
CMS and the Right to
Steal
November
08, 2007
n
CMS Overpaid $4 Billion
n
Willful Injury from Price
Fraud
n
AZ Hospital Pays $5.8 Million
n
More Inquiries at Omnicare
n
A Mother's Vengeance
n
A Thieving Fraud Inspector
n
Adolescent Health Fraud
October
31, 2007
n
Hexcel to Pay $15 Million
n
Novation Out from Under Seal
n
The WellCare Raid
n
Supreme
Court Look at Presentment
n
Quest Braces to Pay
n
Dianon to Pay $1.5 Million
n
Investigation Into
Universal Health Services Expands
October
23, 2007
n
Phony Drug Tests
n
Rigsby Sisters Win "First to File"
n
Grassley to Seek Reelection
October
17, 2007
n
Let's-Make-a-Deal Meals
n
No Gifts, No Entrance
n
Barr Settles for $2 Million
n
Iowa Sues 79 Drug Makers
October
3, 2007
n
Bristol-Myers Squibb To Pay $515
Million
n
Artificial Hip and Knee Co.'s
To Settle for $310 Million
September 26, 2007
n
Needed:
More Resources
n
Keisler Stays on as Acting AG
n
The Gold is in Community Mental
Health Centers
n
HIV Drug Fraud Rampant in FL
n
Tenet Lawyer Now Defendant
n
DoD Whistleblower Protections
September 19, 2007
n
FCA Amendments Introduced
n
Aventis to Pay $190 Million
n
TAF Conference & Awards
n
First New York FCA Case
n
Massive Medicare Theft
n
NY Focuses on Home Heath
n
Tenet Lawyer Sued Under FCA
September 12, 2007
n
FCA
Corrections Act of 2007 is introduced with bipartisan
support from Senate leadership
September 4, 2007
n
Infusion Therapy Fraud
n
Home Health Fraud in NY
n
Missing Weapons in Iraq
n
Louisiana Revises State FCA
August
21, 2007
n
IBM
and PWC Pay $5.2
Million
n
Nursing
Home Violations
n
Screwed for a Washer
n
Worthless Education Loans?
n
Univ.
of Phoenix Loses Again
n
PhRMA
Public Relations
August
14, 2007
n
Crane
Settles for $7.6 Million
n
D.C. Migrant
Farm Workers?
n
Mortgage Fraud Hits the Fan
n
Suit
Against
Iasis Unsealed
n
Parkway
to Pay $1 Million
n
Teradata
Data Warehousing Under Investigation
August
7, 2007
n
A Fraud We Need
Like a Hole in the Head
n
Katrina Suit Out from Under
n
Register Docs on the Take?
July
31, 2007
n
$50 Million Big Dig
Concrete Settlement
n
University Pays $5.3 million
n
The (Ortho)fix Is In
n
Augustine's
Personal Responsibility
n
Keeping an Eye on PSC's
July
24, 2007
n
Maximus to Pay $30.5 Million
n
Crop Support for the Dead
n
HHS and DoJ
Ask for $183 Million More to Fight Fraud
n
CMS: Serving Millions While Tracking Billions
July
17,
2007
n
Department of Insecurity
n
Orphan to pay $20 Million
n
Patients the New Pharma Front?
n
U.S. Joins Lawsuit Against Renal Care
Group
n
Court Flip Flops on Taxes
July
10,
2007
n
Reading the Fine Print at the SEC
n
Cleaning Up the Hurricane
n
Millionaire Doc Wanted More
n
Texas Company Self-discloses
n
Sox:
0 for 947
July
3,
2007
n
Cash for Docs, Drugs for Tots
n
No
More Business as Usual
n
Texas
is Latest State to Pass Muster with HHS
n
New
York's Fantastic Four
n
Growing No-Bid Government
June
26,
2007
n
Judge Saris Weighs in on AWP
n
Texas
Joins 3 Pharma Cases
n
Faulty Flares Ignite Lawsuit
n
Worthless Health Care
n
Phoenix Feels the Heat
n
Hopefully, Beyond Politics
June 19,
2007
n
Giuliani for the Defense
n
Winking at Corporate Crime
n
Medicaid Integrity
n
Medicare Advantage
n
Judge Aims to Prosecute
Whistleblower's Lawyer
n
Predictable Weather?
June 12,
2007
n
A
Prescription for Profit
n
TAF Files Amicus in War
Case
n
U.S. Embassy in Iraq
n
Ambulance Co. Pays $2.5 Million
n
TAF on Medicare Contractors
u
The Complete Newsletter Index
|
|
|
|

|
 |
 |
 |
 |
 |
|

|
McKesson
to Pay $13.25 Million
McKesson Corp, has
agreed to pay $13.25 million to settle charges it did not report
to the DEA the sale of suspicious amounts of controlled
substances sold to pharmacies in Florida, Colorado, Texas, Utah,
California and Maryland. >>
To read more
|
CoxHealth
Floats a Number
CoxHealth Systems
says it may be close to reaching a $60 million settlement with
the U.S. Department of Justice on charges the company upcoded
and billed for services
never performed. However, the company admits negotiations are
far from over. >>
To read more
|
False
Claims Act Amendments, S. 2041,
Voted Out of Senate Judiciary Committee
Senate Bill 2041, the
False Claims Act Corrections Act of
200,
has received overwhelming bipartisan support from the Senate
Judiciary Committee, which has reported it out to the full
Senate for consideration.
"This is common sense legislation that we expect to
sail through the House and Senate," said Jeb White, President of
Taxpayers Against Fraud. "This bill has broad bi-partisan
support. It's hard to be opposed to building a better rat trap
to catch corporate cheats, chiselers, and con artists."
Proponents of S. 2041, note that the new bill clarifies
the existing scope of False Claims Act liability, while closing
a small number of loopholes that have allowed companies to steal
taxpayer dollars with impunity. Specifically, S.2041 would: |
-
Clarify that False Claims Act
liability protects all federal funds;
-
Solely vest the Government
with the power to dismiss whistleblower-filed False Claims
Act lawsuits that are based on public allegations;
-
Remove the confusion over the
statute of limitations period by adopting a straightforward
10-year period;
-
Explicitly clarifies that the
False Claims Act applies to those who discover an
overpayment and decide to pocket the funds;
-
Provide strengthened
employment protection for whistleblowers.
|
S. 2041, and its analog in the
U.S. House of Representatives, is supported by leadership in
both parties, including Sen. Charles Grassley (R-IA), Senator
Richard Durbin D-IL), Senator Patrick Leahy (D-VT), and Senator
Arlen Specter (R-PA). >>
Click here to see TAF's advertisement in Roll Call in
support of the bill (PDF)
|
CVS
Pays $37 Million
For Drug Switching
CVS
Corporation, America’s largest pharmacy chain, has agreed to
pay $37 million to settle charges it illegally overcharged
Medicaid up to 400 percent by switching generic Zantac
(ranitidine) prescriptions from tablets to higher priced
capsules. >>
To read more |
Merck
Settles for $650 Million
Merck
has settled two False Claims Act
cases involving nominal pricing fraud related to the
marketing of three of its top-selling long-term
use drugs,
Zocor, Vioxx and
Pepcid. The marketing
scheme involved Merck offering 92% discounts to hospitals
and clinics provided they filled their prescription needs
with Merck product. The marketing gambit was that once
patients left the hospital, it was expected they would
continue to use the same drugs, with Medicare, Medicaid and
private insurance paying the full price. Discounts tied to sales
performance are considered a kickback and best-price
violation under Medicare and Medicaid rules. >>
To
read more |
Feb. 8, 2008 |
Allison
Engine to Supreme Court
The Supreme Court will hear oral arguments in the
Allison Engine case
this week. Amicus curiae
briefs have been filed by the
Solicitor General's Office
,
Sen. Charles Grassley
and
Taxpayers Against Fraud
. The amici build off the arguments raised in the
Relator-Respondents'
brief and offer
the Court a number of policy considerations for rejecting the
so-called
Totten
"presentment
requirement." On the opposite side of the fence,
representing the company charged with defrauding America's
taxpayers, is
this brief which
asks the Court to reverse the
Sixth Circuit's decision
.
To read more about
the case . |
Feb. 25, 2008 |
$215
Million Alabama Jury Award
Sends Message on Average Wholesale Price Fraud
AstraZeneca was hit with a
$215 million judgment in Alabama
over Medicaid drug pricing fraud. The jury said
AstraZeneca must pay $40
million in compensatory damages and $175 million
in punitive damages for alleged false and misleading reporting
of drug prices reimbursed by the Alabama State Medicaid Agency.
Remember, this is just one drug company in one state. If we
scale up the compensatory award alone, based on population,
AstraZeneca seems to face a potential liability of $2.4 billion
for Average Wholesale Price and Medicaid Best Price violations.
AlstraZeneca is just one of more than 75 drug companies in line
to face similar charges in Alabama. Though the Alabama
litigation is not a False Claims Act case, more than 60
companies face similar charges, under the federal False Claims
Act, up in Boston. These companies include: Abbott, Roxane, Dey,
Boehringer Ingelheim, Amgen, Armour Pharmaceutical; Aventis
Pharmaceuticals, Baxter Healthcare, Bedford Laboratories; Ben
Venue Laboratories, Braun of America, C.H. Boehringer Sohn,
Centocorps Inc., Forest Pharmaceuticals, Grundstucksverwaltung
GMBH & Co., EMD, Geneva Pharmaceuticals, GlaxoSmithKline, Glaxo
Wellcome, Burroughs Wellcome, Hoechst Marion Roussell, Hoffman-LaRoche,
Hospria Inc., Immunex, Ivax Pharmaceuticals, Janssen
Pharmaceutical Products, Johnson & Johnson, Lipha, McGaw, Merck,
Mylan Laboratories, Mylan Pharmaceuticals, Novartis, Ortho
Biotech Products, Pfizer, Pharmacia, Pharma Investment, PurePac
Pharmaceutical, Roche Laboratories, Roxane Laboratories, Sandoz,
Sicor, Gensia Pharmaceuticals, Schering-Plough Corp., SmithKline
Beecham Corp., GlaxoSmithKline, Teva Pharmaceuticals, Warrick
Pharmaceuticals, and Z.L.B. Behring, among others. |
Quest Reserves
$241 Million
Quest Diagnostics has increased its litigation reserves to $241
million, noting that this amount "represents the minimum
expected probable loss" due to False Claims Act litigation
related to the government investigation of NID, a test-kit
manufacturing subsidiary closed in 2006. Settlement talks with
the U.S. Government are ongoing. >>
To read more |
New
Jersey False Claims Act Signed Into Law
It's not often that
both the New Jersey Senate and Assembly give a unanimous
vote in support of a piece of legislation, but that's what
happened with the New Jersey False Claims Act, which has now
been signed into law by Governor John Corzine. >>
For a
complete list of state FCA's
| Jan. 23, 2008 |
HealthSouth
Pays
$14.9 Million
HealthSouth
and two doctors have agreed to pay $14.9 million ($14.2 million
to be paid by the company and $700,000 to be paid by the two
doctors) to settle charges the company was submitting false
claims to Medicare and paying illegal kickbacks to referring
physicians.
The settlement results from
disclosures made by HealthSouth in 2004 and 2005 to the U.S.
Attorney for the Northern District of Alabama.
>>
To read more
|
Dec. 18, 2007 |
Law
and Odor at Wellcare
Wellcare made its General Counsel its Compliance Officer -- the same mistake Tenet did. That's not
the only similarly says Melissa Davis at The Street: both companies
also had big FBI raids, and
both bragged
about their compliance programs which, in hindsight, appear
to have been
gossamer thin. Davis also notes that a whistleblower that filed
a case one day
after the FBI raid is a certified fraud examiner who
supervised WellCare's special investigations
unit.
>>
To read more
|
Dec. 18, 2007 |
Relator
Wins Over DoJ Protest
Jim Marchese,
the former Cell Therapeutics sales rep that
was seeking a
relator's award for helping the government win a $10.5 million FCA
recovery, has won a $1.6
million award despite the DoJ's objections. The Judge agreed that Marchese did
not immediately report the fraud, but said he did not
initiate or plan the activity, and so was eligible for a 15
percent award. >>
To read the opinion
of judge Marsha Pechman
|
Dec. 18, 2007 |
|
$42 Million Sand Theft
In 2001, tugboat captain
Kevin Bartoo filed a case under the California False Claims Act against
Hanson
Building Materials.
The lawsuit charged Hanson with illegally pumping sand
from
Suisun Bay,
and then misreporting the amount of sand mined and its value. Hanson
sold the sand to affiliates at $3.30 per cubic yard, while the affiliates
sold it to others for
$12.50 per cubic yard.
Mr.
Bartoo was awarded
27% of the $42.2 million
settlement, plus a portion of the higher
royalties Hanson
will now be required to pay the State Lands
Commission.
>>
To read more
| Dec. 5, 2007 |
Merck
Settlement Expected to Top $670 Mil.
Merck pharmaceuticals
has reserved $670 million
in expectation of settling a series of False Claims Act cases
involving nominal pricing fraud. FCA lawsuits against Merck
have charged the company with engaging in a kind of kickback
scheme and/or overcharging Medicaid on three of its biggest
selling drugs (Zocor, Vioxx and Pepcid) while giving 92%
discounts on these drugs to private hospitals.
. .Under
the rules governing Medicaid participation, drug companies must
report and give Medicaid the "best price" for their drugs.
Merck not only concealed the deep discounts it gave to
for-profit hospitals, it also tied these deep
discounts
to hospital usage of the named drugs, thereby violating nominal
pricing "safe harbor" provisions meant for charity hospitals and
clinics.
. . Merck's marketing strategy
for Zocor, Vioxx and Pepcid appears to have been a classic
"business plan" fraud: Get patients on long-term drugs for
cholesterol, arthritis pain, and excessive stomach acid while
they are still at the hospital, and then charge Medicaid inflated prices once the
patients left the hospital and went home.
>>
To read the Nevada
complaint for Zocor and
Vioxx, which is believed to
closely parallel a federal complaint still under seal.
>>
To read about the Pepcid
lawsuit
|
Dec..
5, 2007 |
|
$25
Million TVA Coal Settlement
Kinder Morgan has
agreed to pay $25 million to settle a False Claims Act
lawsuit and private claims related to the unauthorized
sales of customer's coal. The FCA settlement
of $19.8 million
represents triple damages for shorting coal to the
Tennessee Valley Authority (TVA), with an additional
$5.2
million to go to settle the claims of private customers.
The case revolved around the improper weighing of coal
after transfer to barges. >>
To read more
|
Dec..
5, 2007
|
False
Claims Act Returns $2 Billion in FY 2007
The Justice Department has announced that $2 billion has been
recovered under the federal False Claims Act in Fiscal Year
2007, of which $1.45 billion came from whistleblower-filed
cases. The total amount returned to the U.S. Government
under the False Claims Act since 1986 is well over $20 billion.
Department of Justice data is actually very conservative, as it
does not include billions of dollars in civil recoveries
returned to the states or criminal fines imposed as a direct
consequence of False Claims Act filings and prosecutions.
>>
To read more from Sen. Grassley
>>
TAF FY 2007 data by
date and case |
Oct..
28, 2007 |
Betting
the House
From the perspective of an FCA lawyer, every case is a
calculated risk, as plaintiff's counsel is only paid if they
prevail, and large fraud cases may be under investigation for
years. Yet, when a case is finally settled, it's rarely noted
that lawyers, as well as relators, have been engaged in a
long-term game of "bet your life." >>
To read more |
Bristol-Myers
Squibb to Pay $515 Million
Bristol-Myers Squibb
has agreed to pay $515 million to settle allegations brought
in seven qui tam cases (six in Boston and one in
Florida) involved pricing and promotional activities (including
kickbacks to doctors) for
more than 50 drugs, including 13 drugs with a combined 2007
sales of $10.7 billion -- a total of 69 percent of
Bristol-Myers' 2007 pharmaceutical revenue. Drugs included in
this settlement include the blood thinner Plavix, antipsychotic
Abilify, the cholesterol treatment Pravachol, the cancer therapy
Taxol, and the antidepressant, Serzone. Of the $515 million,
approximately $328 million will be paid under the Federal False
Claims Act, with the state's getting a total of $187 million. >>
To read more |
Sept.
28, 2007 |
Artificial
Hip and Knee Joint Companies to
Pay $310 Million to Settle Kickback Charges
Five orthotics companies, which account for nearly 95
percent of the hip and knee surgical implants sold in the
United States, have agreed to pay $310 million in order to
avoid criminal prosecution for paying kickbacks to
surgeons in order to get them to choose their products. >>
To read more (PDF)
|Sept. 26, 2007
|
Aventis
to Pay $190 Million
Aventis Pharmaceuticals has agreed to pay over $190
million to resolve charges it was price-gouging
Medicaid on sales of Anzemet, an anti-nausea drug
used primarily in conjunction with oncology and
radiation treatment. Aventis is now known as
sanofi-aventis, and is one of the largest
pharmaceutical manufacturers in the world.
To read more |
September. 10, 2007 |
ConocoPhillips
to Pay
$105
Million
Burlington Resources Inc., a
ConocoPhillips
subsidiary, has agreed to pay the United States $97.5 million
for 17 years worth of fraudulent underpayment of natural gas
royalties from public and Indian lands, plus an additional $7.5
million in lost interest.
The original case charged 17
companies with underpaying oil and natural gas royalties in 21
states. Shell Oil Co. and Dominion Exploration settled
their cases for $56 million and $2 million respectively.
Exxon Mobile and other companies names in the suit have yet to
settle, but assistant attorney general Peter Keisler says "We
will continue to pursue claims against other companies that seek
to evade their royalty payment obligations."
>>
To read more
| | |